RxDoctor Payments Data

Dell White

Optometrist · Fort Myers, FLNPI 1629370721

Payments from drug & device makers

$2,102in general payments, 2019–2025

Across 56 payments — averaging $37.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bausch & Lomb Americas Inc.$544
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$319
  • AbbVie$311
  • Sun Pharmaceutical Industries Inc.$268
  • Tarsus Pharmaceuticals, Inc.$256
  • Aerie Pharmaceuticals, Inc.$153
  • plus $251 from 4 others

What the payments were for

  • Food & beverage$2,102100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,102 in reported general payments places this provider in the 70th percentile of 3,166 optometrist providers in Florida.

See all optometrist providers in Florida

Medicare billing

Part B allowed, 2024
$331,564
Medicare patients
1,821
Services billed
3,478

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine63$80,919
LumiganBimatoprost32$22,125
XiidraLifitegrast12$20,248
Cyclosporine15$15,121
Latanoprost1,004$13,158
CombiganBrimonidine Tartrate/Timolol34$10,903
SimbrinzaBrinzolamide/Brimonidine Tart15$5,707
Tobramycin-DexamethasoneTobramycin/Dexamethasone120$4,808
Travoprost24$3,867
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat204$3,794
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol21$3,061
Timolol Maleate137$2,334
Brimonidine Tartrate142$1,809
Dorzolamide Hcl65$1,554
Prednisolone Acetate31$1,546

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Combigan$311$113,947129 claims
Bausch & Lomb Americas Inc.Xiidra$544$20,24812 claims
AlconSimbrinza$117$5,70715 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 3,166 optometrist providers in Florida.

Other optometrist in Fort Myers

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →